All News
Wipfler et al. Characteristics refractory RA. Associations at baseline (A) and follow-up (B) @RheumNow #ACR22 Abstr#1952 https://t.co/4PJtrDp3Ba https://t.co/x1NCq07Y1h
Richard Conway RichardPAConway ( View Tweet)
Rossato et al. Women in highest tertile ultra-processed food intake 50% more likely to develop SLE than those in lowest tertile. Exacerbated by high BMI. @RheumNow #ACR22 Abstr#1634 https://t.co/T4Bx59VJPX https://t.co/oWaj9QbzgY
Richard Conway RichardPAConway ( View Tweet)
Important late breaker re:barriers to MTX post Roe decision
6% of respondents who tried to fill MTX had barriers to access; most commonly related to pharmacies/pharmacists
This number should be 0%!!
#ACR22 abstr#L09 @RheumNow https://t.co/dgZkJLlL25
Mike Putman EBRheum ( View Tweet)
Pooled data from AURORA 1 and 2 show that Voclosporin maintained reductions in UPCR vs. control over the 3-yr treatment period in pts with #lupus nephritis
#ACR22 @RheumNow ABST#1653 https://t.co/C4n6Yb8bdC
sheila RHEUMarampa ( View Tweet)
Venuturupalli et al. Elevated CASPASE 1 expression in synovial biopsies of inter-critical gout suggest ongoing NLRP3 inflammasome activity between gout attacks. @RheumNow #ACR22 Abstr#1808 https://t.co/OnJOpkRqH9 https://t.co/TGd6pn8Lne
Richard Conway RichardPAConway ( View Tweet)
"FRAX should be done even if DXA T-2.5 score as it will tell you the probability of fracture in the next 10 years" - Dr. M Humphrey Dr. B Humphrey #ACR22 #Osteoporosis Guidelines Session @rheumnow
TheDaoIndex KDAO2011 ( View Tweet)
Adami et al. GCs as low as 2.5mg/day assoc bone loss in RMD. Preventable with anti-resporptives. GC>=5mg/day aHR 2.37 for fracture @RheumNow #ACR22 Abstr#L01 https://t.co/1Q8dDarcAB https://t.co/dW4glkerAL
Richard Conway RichardPAConway ( View Tweet)
Nair et al. HLA-B*5801 allele in African American gout patients. Present in 8%. Higher than expected, ?need for screening pre-allopurinol? @RheumNow #ACR22 Abstr#1793 https://t.co/KrsjQ836BY https://t.co/bmPyqQi7OF
Richard Conway RichardPAConway ( View Tweet)
#ACR22 #Osteoporosis Guidelines Case Example:
The FRAX score needs to be adjusted (multiply by 1.15 or 1.2) in pts who are expected to have cumulative dose >5 grams/year of steroids @rheumnow https://t.co/wF8LP0iZjw
TheDaoIndex KDAO2011 ( View Tweet)
Steroid-sparing in PMR: methotrexate most used, but what is the evidence?
Christian Dejaco says: variable at best.
We need a proper RCT - and it’s on its way. @Sarah_L_Mackie @profbdasgupta @DrMaxYates1 @CatherineL_Hill @drceowen #ACR22 @RheumNow https://t.co/dxaPdVcOPQ
David Liew drdavidliew ( View Tweet)
Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow
Dr. Antoni Chan synovialjoints ( View Tweet)
Ritchlin et al. Bimekizumab in bDMARD naive PsA. 52 week results. Not surprisingly, week 16 outcomes sustained. No joint difference to ADA, skin slightly better @RheumNow #ACR22 Abstr#L02 https://t.co/RjCV8Hb3HR https://t.co/a0NQFyFZlt
Richard Conway RichardPAConway ( View Tweet)
Systemic Inflammation Index (neutrophils*platelet count/lymphocyte count)
predicts survival in RA in 1000+ pts
All cause mortality OR 2.64
CV-mortality OR 3.03
Another proof (if needed) of asso inflammation & mortality in RA
https://t.co/A77iPTTfTM
Abs#1650 #ACR22 @RheumNow https://t.co/8aHYAZEg6v
Aurelie Najm AurelieRheumo ( View Tweet)
Dr. Ogdie proposes a whole-patient care approach to the treat-to-target strategy in SpA with QoL as the most important target.
#ACR22 @Rheumnow @rheumarhyme @trishiemd https://t.co/GjLt2Nym3I
sheila RHEUMarampa ( View Tweet)
Nestor et al. HCQ <5mg/kg day assoc increased hospitalisation for SLE flare. aOR 4.41 (95% CI 1.50-12.98) @RheumNow #ACR22 Abstr#1654 https://t.co/I4bTu2DWaR https://t.co/jpOwHUTenk
Richard Conway RichardPAConway ( View Tweet)
Tuttle et al. Phase 2 RCT of Peresolimab (PD-1 stimulator) in DMARD-IR RA. Evidence of efficacy. No new safety signals @RheumNow #ACR22 Abstr#L03 https://t.co/vhrmtGTjw1 https://t.co/k1LLk95bv1
Richard Conway RichardPAConway ( View Tweet)
#ACR22 #GIO #Osteoporosis Guidelines Case:
"Young skeletons recover bone loss rapidly after GC are discontinued." In these pts, despite daily pred 10 mg/day, they just needs Ca/Vit D, lifestyle mod, and monitoring. @rheumnow https://t.co/a5DVZoB3l8
TheDaoIndex KDAO2011 ( View Tweet)
A new murine model to study Pso and PsA!
Immunodeficient mice NSG-SGM3 🐁 injected w/ serum & PBMCs from Pso and/or PsA pts = pro & arthritis (same phenotype than pts)
Mice skin & synovia >effector memory CD8 T cell & < naïve
https://t.co/cxSvEZC9Ly
Abs#L04 #ACR22 @Rheumnow https://t.co/hfbtSsP3f8
Aurelie Najm AurelieRheumo ( View Tweet)
#ACR22 #GIOP Guidelines Case:
In pt < 40 yo who had renal transplant on 7.5 mg/day or higher with low Z score, consult mineral/metabolism expert but you can consider Rx. @rheumnow https://t.co/RJuRi7EPX1
TheDaoIndex KDAO2011 ( View Tweet)
Are we giving enough HCQ?🤔
Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48)
#ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim
sheila RHEUMarampa ( View Tweet)